Steven Artandi, Director of the Stanford Cancer Institute, shared a post on LinkedIn:
“Heather Wakelee, deputy director of the Stanford Cancer Institute and chief of the Division of Oncology, and I are pleased to announce that Vivek Subbiah, MD, has been appointed as the Stanford Cancer Institute’s inaugural associate director for drug development and precision oncology.
He will lead our Early Drug Development Program, focusing on phase 1 clinical trials, biomarker-driven study design, targeted therapeutics, and rare cancers. Additionally, he will assume a faculty appointment as professor, University Medical Line (UML), in the Stanford Department of Medicine’s Division of Oncology.
Dr. Subbiah is an internationally recognized physician-scientist whose work has significantly advanced early-phase oncology, precision therapeutics, and the development of targeted treatments for rare and molecularly defined cancers. His work has been central to multiple FDA approvals, including tumor-agnostic strategies targeting alterations such as RET and BRAF.
He joins Stanford after a tenure as the chief of early-phase drug development at Sarah Cannon Research Institute. Previously, he held leadership roles at MD Anderson Cancer Center, serving as the executive director of medical oncology research and the clinical medical director in the Division of Cancer Medicine.
Under Dr. Subbiah’s guidance, we look forward to continuing to advance Stanford’s national leadership in early drug development and precision oncology, enhancing access to innovative therapies, and forging new links among discovery, translational research, and patient-centered care.”
Other articles featuring Vivek Subbiah on OncoDaily.